Tempus AI Q1 2026 Revenue Up 36.1%

By Tamara Parker • Tuesday, May 05 16:24 • Permanent Link

Tempus AI reported first-quarter 2026 revenue of $348.1 million, up 36.1% from $255.7 million a year earlier.

Gross profit rose 43.1% to $222.0 million from $155.2 million in the first quarter of 2025.

Diagnostics revenue increased 34.7% to $261.1 million, with oncology volume up 28% and hereditary volume up 54%. Management said hereditary growth was 7% when adjusted for Ambry’s pre-acquisition volumes, given the February closing date. MRD volume reached about 6,500 tests, up roughly 500% year over year.

Data and applications revenue climbed 40.5% to $87.0 million, and insights revenue increased 44.1%.

Loss from operations widened to $84.7 million from $68.7 million a year earlier. Net loss increased to $125.9 million from $68.0 million, while adjusted EBITDA improved to a loss of $2.8 million from a loss of $16.2 million.

Cash and marketable securities totaled $643.8 million at March 31, 2026.

For full-year 2026, Tempus raised revenue guidance to $1.59 billion to $1.60 billion, up from its prior outlook, and kept adjusted EBITDA guidance at about $65 million. The market has reacted to these announcements by moving the company's shares -2.82% to a price of $54.235. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.